PULM vs. ENLV, SPRB, IPA, UBX, BIOR, COCP, QLI, BCTX, EQ, and RNXT
Should you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Enlivex Therapeutics (ENLV), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), Unity Biotechnology (UBX), Biora Therapeutics (BIOR), Cocrystal Pharma (COCP), Qilian International Holding Group (QLI), BriaCell Therapeutics (BCTX), Equillium (EQ), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical preparations" industry.
Enlivex Therapeutics (NASDAQ:ENLV) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 3.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Enlivex Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 414.71%. Pulmatrix has a consensus target price of $10.00, indicating a potential upside of 412.82%. Given Pulmatrix's higher possible upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Pulmatrix.
Enlivex Therapeutics has a net margin of 0.00% compared to Enlivex Therapeutics' net margin of -75.73%. Enlivex Therapeutics' return on equity of -44.05% beat Pulmatrix's return on equity.
Pulmatrix received 147 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 51.72% of users gave Pulmatrix an outperform vote.
Pulmatrix has higher revenue and earnings than Enlivex Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Enlivex Therapeutics' average media sentiment score of 0.22 beat Pulmatrix's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the news media.
Enlivex Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Summary
Pulmatrix beats Enlivex Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Pulmatrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulmatrix Competitors List
Related Companies and Tools
